{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T19:26:51Z","timestamp":1793734011070,"version":"4.6.1"},"reference-count":71,"publisher":"American Association for Cancer Research (AACR)","issue":"6","license":[{"start":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T00:00:00Z","timestamp":1793664000000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030692","name":"Intramural Research Program","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030692","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulators of RAS activity. We found that the phosphatase PP1C dephosphorylated conserved RAS residue T148, permitting LZTR1-dependent proteasomal degradation. LZTR1 was ineffective against KRAS A146 gain-of-function mutations, which lie adjacent to T148 and are enriched in hematologic cancers, such as diffuse large B-cell lymphoma (DLBCL) and acute myeloid leukemia (AML). Remarkably, KRAS protein stability was 4-fold lower in hematologic versus carcinoma cells, revealing a unique therapeutic opportunity targeting RAS protein stability. PAK1 and PAK2 shielded RAS from LZTR1-dependent degradation by phosphorylating T148, and inhibiting PAK1\/2 activity improved RAS-directed therapy. Collectively, these findings reveal a regulatory circuit governing RAS stability that is preferentially active in blood cancers and potentially druggable.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>We found that PP1C and PAK1\/2 regulate RAS T148 phosphorylation, controlling LZTR1-mediated RAS degradation in multiple myeloma, DLBCL, and AML. PAK1\/2 inhibition reduces RAS expression, enhancing the efficacy of RAS-directed therapies in multiple myeloma. Notably, KRAS A146 mutations, prevalent in blood cancers, can shield RAS from this degradation.<\/jats:p>\n                    <jats:p>See related commentary by Boise, p. 860<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2643-3230.bcd-26-0028","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:28:43Z","timestamp":1788193723000},"page":"978-998","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation"],"prefix":"10.1158","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2227-8014","authenticated-orcid":false,"given":"Lin","family":"Zhang","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1585-5429","authenticated-orcid":false,"given":"Arnold","family":"Bolomsky","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9563-6030","authenticated-orcid":false,"given":"Omar S.","family":"Al-Odat","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1957-9895","authenticated-orcid":false,"given":"Callie K.","family":"VanWinkle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-4303-9469","authenticated-orcid":false,"given":"Aaliyah","family":"Battle","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7834-815X","authenticated-orcid":false,"given":"Papiya","family":"Chakraborty","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3337-3984","authenticated-orcid":false,"given":"Ronald J.","family":"Holewinski","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 2 Protein Mass Spectrometry Group, Center for Cancer Research, , , Frederick, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 2 Protein Mass Spectrometry Group, Center for Cancer Research, , , Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9545-2450","authenticated-orcid":false,"given":"Thorkell","family":"Andresson","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 2 Protein Mass Spectrometry Group, Center for Cancer Research, , , Frederick, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 2 Protein Mass Spectrometry Group, Center for Cancer Research, , , Frederick, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-9445-9565","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"H\u00e4upl","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03f6n9m15","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Frankfurt 3 Department of Medicine, Hematology and Oncology, , Goethe University Frankfurt, Frankfurt am Main, Germany."},{"name":"4Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany."},{"name":"5German Cancer Consortium (DKTK), partner site Frankfurt\/Mainz, a partnership between DKFZ and UCT Frankfurt-Marburg, Frankfurt am Main, Germany."},{"name":"6German Cancer Research Center (DKFZ), Heidelberg, Germany."},{"name":"7University Cancer Center (UCT), Frankfurt am Main, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6570-6125","authenticated-orcid":false,"given":"Thomas","family":"Oellerich","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/03f6n9m15","id-type":"ROR","asserted-by":"publisher"}],"name":"University Hospital Frankfurt 3 Department of Medicine, Hematology and Oncology, , Goethe University Frankfurt, Frankfurt am Main, Germany."},{"name":"4Frankfurt Cancer Institute (FCI), Frankfurt am Main, Germany."},{"name":"5German Cancer Consortium (DKTK), partner site Frankfurt\/Mainz, a partnership between DKFZ and UCT Frankfurt-Marburg, Frankfurt am Main, Germany."},{"name":"6German Cancer Research Center (DKFZ), Heidelberg, Germany."},{"name":"7University Cancer Center (UCT), Frankfurt am Main, Germany."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5152-5956","authenticated-orcid":false,"given":"Elizabeth","family":"Hill","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9888-5737","authenticated-orcid":false,"given":"Mehmet","family":"Kocoglu","sequence":"additional","affiliation":[{"name":"8University of Maryland Greenbaum Comprehensive Cancer Center, Baltimore, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5906-8366","authenticated-orcid":false,"given":"Qingcai","family":"Meng","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00adh9b73","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institute of Diabetes and Digestive and Kidney Diseases 9 Laboratory of Cell and Molecular Biology, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 9 Laboratory of Cell and Molecular Biology, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8950-2485","authenticated-orcid":false,"given":"James D.","family":"Phelan","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2639-4226","authenticated-orcid":false,"given":"Jagan","family":"Muppidi","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0706-8019","authenticated-orcid":false,"given":"Ryan M.","family":"Young","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/040gcmg81","id-type":"ROR","asserted-by":"publisher"}],"name":"National Cancer Institute 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."},{"id":[{"id":"https:\/\/ror.org\/01cwqze88","id-type":"ROR","asserted-by":"publisher"}],"name":"National Institutes of Health 1 Lymphoid Malignancies Branch, Center for Cancer Research, , , Bethesda, Maryland."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2026,8,31]]},"reference":[{"key":"2026110303180111200_bib1","doi-asserted-by":"publisher","first-page":"2969","DOI":"10.1158\/0008-5472.CAN-19-3682","article-title":"The frequency of Ras mutations in cancer","volume":"80","author":"Prior","year":"2020","journal-title":"Cancer Res"},{"key":"2026110303180111200_bib2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.ccr.2013.12.015","article-title":"Widespread genetic heterogeneity in multiple myeloma: implications for targeted therapy","volume":"25","author":"Lohr","year":"2014","journal-title":"Cancer Cell"},{"key":"2026110303180111200_bib3","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","article-title":"Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma","volume":"132","author":"Walker","year":"2018","journal-title":"Blood"},{"key":"2026110303180111200_bib4","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1182\/bloodadvances.2019000303","article-title":"Integrated phosphoproteomics and transcriptional classifiers reveal hidden RAS signaling dynamics in multiple myeloma","volume":"3","author":"Lin","year":"2019","journal-title":"Blood Adv"},{"key":"2026110303180111200_bib5","doi-asserted-by":"publisher","first-page":"14293","DOI":"10.1002\/cam4.6103","article-title":"Plasma cell myeloma with RAS\/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis","volume":"12","author":"Li","year":"2023","journal-title":"Cancer Med"},{"key":"2026110303180111200_bib6","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1038\/leu.2008.142","article-title":"Clinical and biological significance of RAS mutations in multiple myeloma","volume":"22","author":"Chng","year":"2008","journal-title":"Leukemia"},{"key":"2026110303180111200_bib7","doi-asserted-by":"publisher","first-page":"3911","DOI":"10.1200\/JCO.2014.59.1503","article-title":"Mutational spectrum, copy number changes, and outcome: results of a sequencing study of patients with newly diagnosed myeloma","volume":"33","author":"Walker","year":"2015","journal-title":"J Clin Oncol"},{"key":"2026110303180111200_bib8","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1182\/blood.v88.7.2699.bloodjournal8872699","article-title":"Activating mutations of N- and K-ras in multiple myeloma show different clinical associations: analysis of the Eastern Cooperative Oncology Group Phase III Trial","volume":"88","author":"Liu","year":"1996","journal-title":"Blood"},{"key":"2026110303180111200_bib9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"2026110303180111200_bib10","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/bjh.13258","article-title":"RAS mutation status and bortezomib therapy for relapsed multiple myeloma","volume":"169","author":"Smith","year":"2015","journal-title":"Br J Haematol"},{"key":"2026110303180111200_bib11","doi-asserted-by":"publisher","first-page":"27854","DOI":"10.18632\/oncotarget.15718","article-title":"The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma","volume":"8","author":"Stein","year":"2017","journal-title":"Oncotarget"},{"key":"2026110303180111200_bib12","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","article-title":"Targeting RAS signalling pathways in cancer therapy","volume":"3","author":"Downward","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2026110303180111200_bib13","doi-asserted-by":"publisher","first-page":"eadk0775","DOI":"10.1126\/science.adk0775","article-title":"Defining the KRAS- and ERK-dependent transcriptome in KRAS-mutant cancers","volume":"384","author":"Klomp","year":"2024","journal-title":"Science"},{"key":"2026110303180111200_bib14","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1038\/s41586-022-05086-1","article-title":"Structure of the MRAS-SHOC2-PP1C phosphatase complex","volume":"609","author":"Hauseman","year":"2022","journal-title":"Nature"},{"key":"2026110303180111200_bib15","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/s41586-022-04838-3","article-title":"Structural basis for SHOC2 modulation of RAS signalling","volume":"609","author":"Liau","year":"2022","journal-title":"Nature"},{"key":"2026110303180111200_bib16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1038\/s41586-022-04928-2","article-title":"Structure-function analysis of the SHOC2-MRAS-PP1C holophosphatase complex","volume":"609","author":"Kwon","year":"2022","journal-title":"Nature"},{"key":"2026110303180111200_bib17","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41586-025-08931-1","article-title":"Targeting the SHOC2-RAS interaction in RAS-mutant cancers","volume":"642","author":"Hauseman","year":"2025","journal-title":"Nature"},{"key":"2026110303180111200_bib18","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.molcel.2006.03.027","article-title":"A phosphatase holoenzyme comprised of Shoc2\/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity","volume":"22","author":"Rodriguez-Viciana","year":"2006","journal-title":"Mol Cell"},{"key":"2026110303180111200_bib19","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1038\/370527a0","article-title":"Phosphatidylinositol-3-OH kinase as a direct target of Ras","volume":"370","author":"Rodriguez-Viciana","year":"1994","journal-title":"Nature"},{"key":"2026110303180111200_bib20","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1126\/science.adv2684","article-title":"Covalent inhibitors of the PI3K\u03b1 RAS binding domain impair tumor growth driven by RAS and HER2","volume":"390","author":"Klebba","year":"2025","journal-title":"Science"},{"key":"2026110303180111200_bib21","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1038\/s41467-022-33142-x","article-title":"Oncogenic RAS commandeers amino acid sensing machinery to aberrantly activate mTORC1 in multiple myeloma","volume":"13","author":"Yang","year":"2022","journal-title":"Nat Commun"},{"key":"2026110303180111200_bib22","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1056\/nejmoa2103695","article-title":"Sotorasib for lung cancers with KRAS p.G12C mutation","volume":"384","author":"Skoulidis","year":"2021","journal-title":"N Engl J Med"},{"key":"2026110303180111200_bib23","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1056\/nejmoa2204619","article-title":"Adagrasib in non-small-cell lung cancer harboring a KRASG12C mutation","volume":"387","author":"J\u00e4nne","year":"2022","journal-title":"N Engl J Med"},{"key":"2026110303180111200_bib24","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1038\/s41467-021-22125-z","article-title":"The origins and genetic interactions of KRAS mutations are allele- and tissue-specific","volume":"12","author":"Cook","year":"2021","journal-title":"Nat Commun"},{"key":"2026110303180111200_bib25","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.ccell.2024.05.026","article-title":"IRF4 requires ARID1A to establish plasma cell identity in multiple myeloma","volume":"42","author":"Bolomsky","year":"2024","journal-title":"Cancer Cell"},{"key":"2026110303180111200_bib26","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1038\/s43018-024-00784-3","article-title":"The proteogenomic landscape of multiple myeloma reveals insights into disease biology and therapeutic opportunities","volume":"5","author":"Ramberger","year":"2024","journal-title":"Nat Cancer"},{"key":"2026110303180111200_bib27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1038\/nbt.3437","article-title":"Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9","volume":"34","author":"Doench","year":"2016","journal-title":"Nat Biotechnol"},{"key":"2026110303180111200_bib28","doi-asserted-by":"publisher","first-page":"2229","DOI":"10.1042\/BST20200503","article-title":"Protein phosphatase-1: dual activity regulation by inhibitor-2","volume":"48","author":"Lemaire","year":"2020","journal-title":"Biochem Soc Trans"},{"key":"2026110303180111200_bib29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1042\/BST20160154","article-title":"Biogenesis and activity regulation of protein phosphatase 1","volume":"45","author":"Verbinnen","year":"2017","journal-title":"Biochem Soc Trans"},{"key":"2026110303180111200_bib30","doi-asserted-by":"publisher","first-page":"eaag1796","DOI":"10.1126\/scisignal.aag1796","article-title":"Genomics and evolution of protein phosphatases","volume":"10","author":"Chen","year":"2017","journal-title":"Sci Signal"},{"key":"2026110303180111200_bib31","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1146\/annurev-biochem-062917-012332","article-title":"Protein serine\/threonine phosphatases: keys to unlocking regulators and substrates","volume":"87","author":"Brautigan","year":"2018","journal-title":"Annu Rev Biochem"},{"key":"2026110303180111200_bib32","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1091\/mbc.E15-12-0844","article-title":"An improved smaller biotin ligase for BioID proximity labeling","volume":"27","author":"Kim","year":"2016","journal-title":"Mol Biol Cell"},{"key":"2026110303180111200_bib33","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1042\/BJ20060678","article-title":"Protein phosphatase 1 regulates the stability of the circadian protein PER2","volume":"399","author":"Gallego","year":"2006","journal-title":"Biochem J"},{"key":"2026110303180111200_bib34","doi-asserted-by":"publisher","first-page":"3433","DOI":"10.1016\/j.apsb.2021.02.014","article-title":"Targeting RAS phosphorylation in cancer therapy: mechanisms and modulators","volume":"11","author":"Qiu","year":"2021","journal-title":"Acta Pharm Sin B"},{"key":"2026110303180111200_bib35","doi-asserted-by":"publisher","first-page":"D512","DOI":"10.1093\/nar\/gku1267","article-title":"PhosphoSitePlus, 2014: mutations, PTMs and recalibrations","volume":"43","author":"Hornbeck","year":"2015","journal-title":"Nucleic Acids Res"},{"key":"2026110303180111200_bib36","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/nbt0502-473","article-title":"Protein detection using proximity-dependent DNA ligation assays","volume":"20","author":"Fredriksson","year":"2002","journal-title":"Nat Biotechnol"},{"key":"2026110303180111200_bib37","doi-asserted-by":"publisher","first-page":"e0250239","DOI":"10.1371\/journal.pone.0250239","article-title":"Identification of ubiquitination-related genes in human glioma as indicators of patient prognosis","volume":"16","author":"Wang","year":"2021","journal-title":"PLoS One"},{"key":"2026110303180111200_bib38","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1126\/science.aap7607","article-title":"Mutations in LZTR1 drive human disease by dysregulating RAS ubiquitination","volume":"362","author":"Steklov","year":"2018","journal-title":"Science"},{"key":"2026110303180111200_bib39","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1126\/science.aap8210","article-title":"LZTR1 is a regulator of RAS ubiquitination and signaling","volume":"362","author":"Bigenzahn","year":"2018","journal-title":"Science"},{"key":"2026110303180111200_bib40","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1126\/science.aav1444","article-title":"RIT1 oncoproteins escape LZTR1-mediated proteolysis","volume":"363","author":"Castel","year":"2019","journal-title":"Science"},{"key":"2026110303180111200_bib41","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","article-title":"Gene ontology: tool for the unification of biology. The Gene Ontology Consortium","volume":"25","author":"Ashburner","year":"2000","journal-title":"Nat Genet"},{"key":"2026110303180111200_bib42","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1126\/science.adv7088","article-title":"Structural basis for LZTR1 recognition of RAS GTPases for degradation","volume":"389","author":"Dharmaiah","year":"2025","journal-title":"Science"},{"key":"2026110303180111200_bib43","doi-asserted-by":"publisher","first-page":"114448","DOI":"10.1016\/j.celrep.2024.114448","article-title":"Mutation-induced LZTR1 polymerization provokes cardiac pathology in recessive Noonan syndrome","volume":"43","author":"Busley","year":"2024","journal-title":"Cell Rep"},{"key":"2026110303180111200_bib44","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41586-024-07487-w","article-title":"Accurate structure prediction of biomolecular interactions with AlphaFold 3","volume":"630","author":"Abramson","year":"2024","journal-title":"Nature"},{"key":"2026110303180111200_bib45","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","article-title":"Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes","volume":"56","author":"Skerget","year":"2024","journal-title":"Nat Genet"},{"key":"2026110303180111200_bib46","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1158\/2159-8290.CD-18-1220","article-title":"Tissue-specific oncogenic activity of KRASA146T","volume":"9","author":"Poulin","year":"2019","journal-title":"Cancer Discov"},{"key":"2026110303180111200_bib47","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s13059-021-02540-7","article-title":"Chronos: a cell population dynamics model of CRISPR experiments that improves inference of gene fitness effects","volume":"22","author":"Dempster","year":"2021","journal-title":"Genome Biol"},{"key":"2026110303180111200_bib48","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41586-019-1694-1","article-title":"The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity","volume":"575","author":"Canon","year":"2019","journal-title":"Nature"},{"key":"2026110303180111200_bib49","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/nejmoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"key":"2026110303180111200_bib50","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"key":"2026110303180111200_bib51","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1038\/s41408-024-01054-2","article-title":"RAS mutations in myeloid malignancies: revisiting old questions with novel insights and therapeutic perspectives","volume":"14","author":"Alawieh","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026110303180111200_bib52","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1182\/blood.v97.3.729","article-title":"Activated fibroblast growth factor receptor 3 is an oncogene that contributes to tumor progression in multiple myeloma","volume":"97","author":"Chesi","year":"2001","journal-title":"Blood"},{"key":"2026110303180111200_bib53","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/nchembio.2103","article-title":"Small-molecule binding of the axin RGS domain promotes \u03b2-catenin and Ras degradation","volume":"12","author":"Cha","year":"2016","journal-title":"Nat Chem Biol"},{"key":"2026110303180111200_bib54","doi-asserted-by":"publisher","first-page":"6785","DOI":"10.1016\/j.bmc.2010.07.045","article-title":"Novel indolylmaleimide acts as GSK-3beta inhibitor in human neural progenitor cells","volume":"18","author":"Schm\u00f6le","year":"2010","journal-title":"Bioorg Med Chem"},{"key":"2026110303180111200_bib55","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1158\/2159-8290.CD-24-0027","article-title":"Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers","volume":"14","author":"Jiang","year":"2024","journal-title":"Cancer Discov"},{"key":"2026110303180111200_bib56","doi-asserted-by":"publisher","first-page":"ra30","DOI":"10.1126\/scisignal.2002242","article-title":"Ras stabilization through aberrant activation of Wnt\/\u03b2-catenin signaling promotes intestinal tumorigenesis","volume":"5","author":"Jeong","year":"2012","journal-title":"Sci Signal"},{"key":"2026110303180111200_bib57","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1016\/s0092-8674(00)00122-7","article-title":"Linking colorectal cancer to Wnt signaling","volume":"103","author":"Bienz","year":"2000","journal-title":"Cell"},{"key":"2026110303180111200_bib58","doi-asserted-by":"publisher","first-page":"5065","DOI":"10.1074\/jbc.M509073200","article-title":"The BTB-kelch protein LZTR-1 is a novel Golgi protein that is degraded upon induction of apoptosis","volume":"281","author":"Nacak","year":"2006","journal-title":"J Biol Chem"},{"key":"2026110303180111200_bib59","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bbamcr.2008.10.016","article-title":"Sorting of lysosomal proteins","volume":"1793","author":"Braulke","year":"2009","journal-title":"Biochim Biophys Acta"},{"key":"2026110303180111200_bib60","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1158\/1541-7786.MCR-16-0369","article-title":"Deubiquitinase USP18 loss mislocalizes and destabilizes KRAS in lung cancer","volume":"15","author":"Mustachio","year":"2017","journal-title":"Mol Cancer Res"},{"key":"2026110303180111200_bib61","doi-asserted-by":"publisher","first-page":"13362","DOI":"10.1021\/acsomega.3c00804","article-title":"In silico analysis of nsSNPs of human KRAS gene and protein modeling using bioinformatic tools","volume":"8","author":"Xu","year":"2023","journal-title":"ACS Omega"},{"key":"2026110303180111200_bib62","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/s0960-9822(97)70091-5","article-title":"Human p21-activated kinase (Pak1) regulates actin organization in mammalian cells","volume":"7","author":"Sells","year":"1997","journal-title":"Curr Biol"},{"key":"2026110303180111200_bib63","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1136\/gutjnl-2014-306768","article-title":"Tracing PAKs from GI inflammation to cancer","volume":"63","author":"Dammann","year":"2014","journal-title":"Gut"},{"key":"2026110303180111200_bib64","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nature09837","article-title":"Initial genome sequencing and analysis of multiple myeloma","volume":"471","author":"Chapman","year":"2011","journal-title":"Nature"},{"key":"2026110303180111200_bib65","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/978-1-4939-9151-8_16","article-title":"Protocols for CRISPR-Cas9 screening in lymphoma cell lines","volume":"1956","author":"Webster","year":"2019","journal-title":"Methods Mol Biol"},{"key":"2026110303180111200_bib66","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol"},{"key":"2026110303180111200_bib67","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41586-018-0290-0","article-title":"A multiprotein supercomplex controlling oncogenic signalling in lymphoma","volume":"560","author":"Phelan","year":"2018","journal-title":"Nature"},{"key":"2026110303180111200_bib68","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1038\/nmeth.2019","article-title":"Fiji: an open-source platform for biological-image analysis","volume":"9","author":"Schindelin","year":"2012","journal-title":"Nat Methods"},{"key":"2026110303180111200_bib69","doi-asserted-by":"publisher","first-page":"W305","DOI":"10.1093\/nar\/gkp427","article-title":"ToppGene Suite for gene list enrichment analysis and candidate gene prioritization","volume":"37","author":"Chen","year":"2009","journal-title":"Nucleic Acids Res"},{"key":"2026110303180111200_bib70","doi-asserted-by":"publisher","first-page":"W404","DOI":"10.1093\/nar\/gkad350","article-title":"PAE viewer: a webserver for the interactive visualization of the predicted aligned error for multimer structure predictions and crosslinks","volume":"51","author":"Elfmann","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"2026110303180111200_bib71","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1002\/pro.3943","article-title":"UCSF ChimeraX: structure visualization for researchers, educators, and developers","volume":"30","author":"Pettersen","year":"2021","journal-title":"Protein Sci"}],"container-title":["Blood Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0028\/3826174\/bcd-26-0028.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/doi\/10.1158\/2643-3230.BCD-26-0028\/3837443\/bcd-26-0028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/978\/3844283\/bcd-26-0028.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article-pdf\/7\/6\/978\/3844283\/bcd-26-0028.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T08:18:09Z","timestamp":1793693889000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/bloodcancerdiscov\/article\/7\/6\/978\/789645\/Phosphorylation-Protects-Oncogenic-RAS-from-LZTR1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,31]]},"references-count":71,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8,31]]},"published-print":{"date-parts":[[2026,11,3]]}},"URL":"https:\/\/doi.org\/10.1158\/2643-3230.bcd-26-0028","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/2643-3230.34897793","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34897796","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34897808","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34897805","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34897814","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34897802","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34897811","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2643-3230.34897799","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/2643-3230.c.8814725","asserted-by":"object"}]},"ISSN":["2643-3230","2643-3249"],"issn-type":[{"value":"2643-3230","type":"print"},{"value":"2643-3249","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,31]]}}}